RedHill Biopharma Ltd. (RDHL)
| Market Cap | 5.34M |
| Revenue (ttm) | 286,000 |
| Net Income (ttm) | -429,000 |
| Shares Out | 6.08M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,908 |
| Open | 0.860 |
| Previous Close | 0.860 |
| Day's Range | 0.860 - 0.943 |
| 52-Week Range | 0.710 - 3.310 |
| Beta | 4.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 27, 2026 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; ... [Read more]
Financial Performance
Financial StatementsNews
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- ...
RedHill Biopharma announces $19.4M private placement
RedHill Biopharma (RDHL) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 8,571,429 American Depositary Shares, each ADS representing ten thousand...
RedHill Biopharma Announces Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- Re...
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
RedHill Biopharma Ltd. ($RDHL) is a specialty biopharmaceutical company focused on developing and commercializing treatments in areas including gastrointestinal diseases, infectious diseases, oncology...
RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst
RedHill Biopharma Ltd. (NASDAQ:RDHL) is a specialty biopharmaceutical company focused on the U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and onc...
RedHill Biopharma’s opaganib granted FDA Rare Pediatric Disease designation
RedHill Biopharma (RDHL) announced that the FDA has granted rare pediatric disease, or RPD, designation to opaganib for treatment of neuroblastoma, or NB. The FDA grant of rare pediatric disease…
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young c...
RedHill Biopharma launches enforcement of $11M judgment against Kukbo
RedHill Biopharma (RDHL) announced that it has commenced recognition and enforcement proceedings in Korea in respect of the New York Supreme Court’s final judgment in favor of RedHill against Kukbo…
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively d...
Bessor Announces Entering Option for the Redhill Property
Vancouver, BC, May 26, 2026 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) announces that, on February 9, 2026, it entered into an agreement (the “Agreement”) with...
RedHill Biopharma Slides: Corporate presentation
RedHill Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on May 17, 2026.
RedHill Biopharma’s RHB-204 shows efficacy in Crohn’s Disease
RedHill Biopharma (RDHL) announced new in vitro testing results demonstrating RHB-204’s comparability to RHB-104 in Mycobacterium avium subspecies paratuberculosis, or MAP, killing efficacy. Oral RHB-...
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium ...
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partners...
RedHill Biopharma announces presentation of preclinical data on opaganib at AACR
RedHill Biopharma (RDHL) announced the independent presentation of new preclinical data at the 2026 American Association for Cancer Research, or AACR, Annual Meeting, showing positive effects of opaga...
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on thera...
RedHill Biopharma Slides: Corporate presentation
RedHill Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on April 6, 2026.
RedHill Biopharma announces full sales and operational launch of Talicia
RedHill Biopharma (RDHL) announced that the full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings, or THI, and Cumberland Pharmaceuticals (...
Joint U.S. Commercialization of RedHill's Talicia® Commences
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and...
RedHill Biopharma announces development progress for RHB-102
RedHill Biopharma (RDHL) announced development progress for RHB-102 in multiple GI indications, including its development, via the accelerated FDA 505(b)(2) route, as a once-daily oral ondansetron the...
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
RHB-102 1 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis ...
RedHill Biopharma announces in vivo results on opaganib, venetoclax
RedHill Biopharma (RDHL) announced positive in vivo results, indicating that opaganib combined with venetoclax reduces Chronic Lymphocytic Leukemia, CLL, cells by half compared to controls, and furthe...
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic...
RedHill Biopharma regains compliance with Nasdaq equity requirement
RedHill Biopharma (RDHL) announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market that the Company has regained compliance with the stockholders’ equity requirement s...